Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:03:23.475Z.
Calculation as of: 2026-10-06T21:03:23.475Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a4f1da35868143a3e9cc9e15baeeae426ebbcf8636af82277700bcf7ee6cbb8a
PEG RATIO
N/A
Sera Prognostics, Inc.
Market Cap
$78.29M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Sera Prognostics, Inc. (SERA) | $78.29M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
